Biomea Fusion Q2 net loss narrows to $20.7M, raises $42.8M, pipeline advances

Biomea Fusion, Inc.

2025-Q2 EPS reported -$1.29 vs consensus -$0.54 ▼ miss (-138.4%)

Net loss $20.7M (Q2 2025) vs $37.3M (Q2 2024); R&D expenses halved to $16.6M.
Raised ~$42.8M gross from public offering; cash runway extended into H2 2026.
Icovamenib at ADA 2025: durable HbA1c reduction, enhanced beta-cell function; combo with semaglutide showed superior glycemic control and weight loss with lean mass preservation.
BMF-650 achieved up to 15% weight loss in obese monkeys; IND submission on track for H2 2025.
Workforce reduced; quarterly expenses expected ~40% lower; oncology program BMF-500 ended, seeking partnerships.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.